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CANDIDEMIA IN A BRAZILIAN TERTIARY CARE HOSPITAL: SPECIES DISTRIBUTION AND
ANTIFUNGAL SUSCEPTIBILITY PATTERNS
Ana Graciela Ventura ANTUNES(1), Alessandro Comarú PASQUALOTTO(2), María Cristina DIAZ(3), Pedro Alves d´AZEVEDO(1) & Luiz Carlos SEVERO(4)
SUMMARY
Recent studies have shown differences in the epidemiology of invasive infections caused by Candida species worldwide. In the
period comprising August 2002 to August 2003, we performed a study in Santa Casa Complexo Hospitalar, Brazil, to determine
Candida species distribution associated with candidemia and their antifungal susceptibility profiles to amphotericin B, fluconazole
and itraconazole. Antifungal susceptibility was tested according to the broth microdilution method described in the NCCLS (M27A-
2 method). Only one sample from each patient was analyzed (the first isolate). Most of the episodes had been caused by species other
than C. albicans (51.6%), including C. parapsilosis (25.8%), C. tropicalis (13.3%), C. glabrata (3.3%), C. krusei (1.7%), and others
(7.5%). Dose-dependent susceptibility to itraconazole was observed in 14.2% of strains, and dose-dependent susceptibility to fluconazole
was found in 1.6%. Antifungal resistance was not found, probably related to low use of fluconazole. Further epidemiological surveillance
is needed.
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INTRODUCTION
The term candidemia indicates the presence of Candida species in the
blood. With the growing number of immunodepressed patients, antibiotic
and antifungal use, epidemiology of candidemia has changed in recent
years, with emergence of species with reduced susceptibility to antifungal
agents5. Studies performed in different countries, however, have shown
different susceptibility patterns2, reinforcing the need of further research.
In this study, we analyze the Candida species causing candidemia and
their antifungal susceptibility patterns in a large Brazilian hospital.
MATERIAL AND METHODS
This transversal study included all bloodstream isolates of Candida
spp. collected from patients admitted at Santa Casa Complexo Hospitalar,
a tertiary care hospital with 1200 beds, from August 2002 to August
2003. To avoid the inclusion of several samples from the same patient,
which should bias Candida species distribution, just one sample from
each patient was analyzed (the first isolate). Germ tubes were performed,
and negative strains were identified through kit ID 32C (BioMérieux
SA, France).
Antifungal susceptibility was tested according to the broth
microdilution method described in the National Committee for Clinical
Laboratory Standards (M27-A2)9. In accordance to this protocol, the
following antifungal drugs were tested: amphotericin B (Sigma Chemical
Corporation, USA), fluconazole, (Pfizer Inc., USA) and itraconazole
(Janssen Pharmaceutica, USA). Broth microdilution testing was
performed in RPMI-1640 with L-glutamine, without bicarbonate (Gibco
Invitrogen Corporation, USA), buffered with MOPS at pH 7.0. The plates
were incubated at 35 oC for 48 hours, visually read, and then corroborated
through an ELISA reader. The minimum inhibitory concentration (MIC)
for amphotericin B was defined as the lowest concentration that showed
reduction in the turbidity. The MIC for itraconazole and fluconazole
was defined as the concentration that showed prominent reduction in
the turbidity when compared to a positive control.
Strain susceptibility to fluconazole and itraconazole were classified
as susceptible (MIC ≤ 8 µg/mL and MIC ≤ 0.125 µg/mL), susceptible-
dose dependent (MIC 16 - 32 µg/mL and MIC 0.25 - 0.5 µg/mL) and
resistant (MIC > 32 µg/mL and MIC > 0.5 µg/mL, respectively)9.
Although there are no established breakpoints for amphotericin B, most
susceptible strains show MIC ≤ 1 µg/mL, and that concentration was
used to define susceptibility. The control was performed by using standard
strains ATCC (American Type Culture Collection): C. krusei ATCC®
6258 and C. parapsilosis ATCC® 22019. The protocol was approved by
institutional review board/independent ethics committee, and the authors
declare no conflict of interests to write this manuscript. To confirm species
and susceptibility, strains were submitted to Department of Pathology,
University of Iowa.
240
ANTUNES, A.G.V.; PASQUALOTTO, A.C.; DIAZ, M.C.; D’AZEVEDO, P.A. & SEVERO, L.C. - Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal
susceptibility patterns. Rev. Inst. Med. trop. S. Paulo, 46(5):239-241, 2004.
RESULTS
From August 2002 to August 2003, a total of 120 isolates were
recovered from patients with candidemia (Table 1). C. albicans (48.3%)
was the most prevalent one, followed by C. parapsilosis (25.8%), and
C. tropicalis (13.3%). No resistant strain was found. Dose-dependent
susceptibility to itraconazole was observed in isolates of C. krusei (50%),
C. glabrata (25%), C. parapsilosis (16%), C. tropicalis (12%), and C.
albicans (7%). Dose-dependent susceptibility to fluconazole was found
only in C. krusei isolates; all strains of C. glabrata were susceptible to
fluconazole.
DISCUSSION
In the present study, we showed that most episodes of candidemia at
our institution were caused by species other than C. albicans (51.6%).
Added, C. glabrata and C. krusei accounted for only 5.0% of all cases.
The distribution of species with reduced susceptibility to azoles, mainly
C. glabrata, has shown large variations in different regions of the world.
While C. glabrata is the second most prevalent species in the United
States2,10,11, it is infrequent in South America, contrasting with C.
parapsilosis and C. tropicalis2,6,12. In Brazil, C. albicans has been the
main agent of candidemia (20-50%), followed by C. parapsilosis (17-
35%), C. tropicalis (12-27%), and C. guilliermondii (2-10%)1,4,7,8. C.
krusei has been an infrequent cause of candidemia worldwide (1-2%)1,10,12.
In accordance to our findings, previous studies in South America
have shown low rate of antifungal resistance3,6. GODOY et al.6 found
that most Candida spp. isolates were susceptible to all antifungal agents.
In a Brazilian study with 200 cases of candidemia, despite the high rate
of infections caused by species other than C. albicans (60%, mainly C.
tropicalis and C. parapsilosis), COLOMBO et al.3 found that resistance
to azoles occurred in only 1.5% of isolates. In the same study, two isolates
of C. krusei and 11% of isolates of C. glabrata were resistant to
fluconazole.
SENTRY studies11 showed that there was low resistance to azoles in
samples collected in Canada and South America when compared to
samples collected in the United States. The less frequent use of
fluconazole may explain the low resistance to azoles found in those
studies. We have found only two isolates of C. krusei in this study, both
of it were susceptible-dose dependent to fluconazole (confirmed by
repetition). However, it is known that this species is intrinsically resistant
to it5.
Concluding, our study confirmed data from previous studies that
demonstrated high prevalence of candidemia in Brazil caused by species
other than C. albicans1,4,7. Resistance to antifungal agents was not found,
and this finding may at least partially be explained by the low use of
fluconazole. Epidemiological surveillance, however, is necessary, in order
to follow the dynamics of candidemia.
 RESUMO
Candidemia em hospital terciário brasileiro: distribuição das
espécies e padrões de susceptibilidade aos antifúngicos
Estudos realizados em diferentes países têm mostrado diferença na
epidemiologia das infecções invasivas por Candida spp. No período de
agosto de 2002 a agosto de 2003, foi conduzido estudo na Santa Casa
Complexo Hospitalar, Porto Alegre, Brasil, para determinar a distribuição
das espécies de Candida associadas a candidemia e o perfil de
susceptibilidade das mesmas aos antifúngicos anfotericina B, fluconazol
e itraconazol. Os testes de susceptibilidade foram realizados de acordo
Table 1
Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Santa Casa Complexo Hospitalar (n = 120)
between August 2002 and August 2003
Species n (%) Antifungal agents MIC Range (µg/mL) Suscept. (%) Susceptible dose dep. (%) Resistant  (%)
C. albicans 58 Amphotericin B 0.25 – 1.00 100% – –
(48.3) Fluconazole 0.12 – 8.00 100% – –
Itraconazole 0.03 – 0.25 93% 7% –
C. parapsilosis 31 Amphotericin B 0.12 –1.00 100% – –
(25.8) Fluconazole 0.12 – 2.00 100% – –
Itraconazole 0.03 – 0.50 84% 16% –
C. tropicalis 16 Amphotericin B 0.5 – 1.00 100% – –
(13.3) Fluconazole 0.12 – 2.00 100% – –
Itraconazole 0.03 – 0.25 88% 12% –
C. glabrata 4 Amphotericin B 0.50 – 1.00 100% – –
(3.3) Fluconazole 1.00 – 8.00 100% – –
Itraconazole 0.12 – 0.25 75% 25% –
C. krusei 2 Amphotericin B 0.50 – 1.00 100% – –
(1.7) Fluconazole 16.00 – 16.00 – 100% –
Itraconazole 0.06 – 0.50 50% 50% –
Other species * 9 Amphotericin B 0.25 – 1.00 100% – –
(7.5) Fluconazole 0.25 – 4.00 100% – –
Itraconazole 0.03 – 0.50 56% 44% –
* Other species included C. famata (n = 2), C. sake (n = 2), C. guillermondii (n = 2), C. lusitaniae (n = 1), C. dubliniensis (n = 1), C. lipolytica (n = 1).
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com a metodologia M27-A2 padronizada pelo NCCLS. Foi incluído no
estudo o primeiro isolado de hemocultivo de cada paciente. A maioria
dos episódios (51,6%) ocorreu por espécies outras que C. albicans,
incluindo C. parapsilosis (25,8%), C. tropicalis (13,3%), C. glabrata
(3,3%), C. krusei (1,7%) e outras espécies (7,5%). Não foi encontrada
resistência aos antifúngicos testados, possivelmente devido ao baixo
consumo de fluconazol na Instituição. Susceptibilidade dose-dependente
ao itraconazol ocorreu em 14,2% e ao fluconazol 1,6%. Faz-se necessário
monitoramento epidemiológico.
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